Skip to main content
. 2024 Oct 24;15:1473284. doi: 10.3389/fneur.2024.1473284

Figure 3.

Figure 3

Components driving NEDA-3.a *p < 0.0001. aParticipants may have > 1 component of evidence of disease activity. bIndependent Relapse Adjudication Committee confirmed. Pooled post hoc analysis. Modified intention-to-treat population. CDP, confirmed disease progression; Gd+, gadolinium-enhancing; NEDA-3, 3-parameter no evidence of disease activity. (A) Free of relapse. (B) Free of Gd+ T1 lesions. (C) Free of new/enlarging T2 lesions. (D) Free of 12-week CDP.